Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Individualized antipsychotic care in schizophrenia spectrum disorders
2021-003588-85Phase 4Completed
- Sponsor
- UCLouvain
- Start
- Oct 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4 trial of olanzapine, risperidone and aripiprazole in schizophrenia and schizoaffective disorder (3 arms), sponsored by UCLouvain. Primary endpoint: Correlation between plasma antipsychotic concentrations and genetic polymorphism. Started Oct 2021; status: completed.
02
Drugs
olanzapinerisperidonearipiprazole
03
Conditions
schizophreniaschizoaffective disorder
Beyond the preview
Go deeper on 2021-003588-85.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-003588-85.